
Myeloproliferative Neoplasms (MPN)
Latest Content
Latest Videos

More News

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.

Outcomes in accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasm (MPN) differ from AML, and AML-based frameworks may not fully capture prognosis in this population.

Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, though more research into the links is needed.

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

The QRISK3 assessment is designed for the general population, but it appears to also have utility in patients with essential thrombosis and polycythemia vera.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

A recent study suggests hemorrhagic events following essential thrombocythemia diagnosis are among the most significant predictors of early death.

The study found that atrial fibrillation (AF) significantly increases stroke and mortality risk in certain patients with myeloproliferative neoplasms (MPNs).

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering a practical strategy that does not compromise efficacy.

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

The findings highlight the limits of risk stratification algorithms based on data from older patients.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with myelofibrosis (MF) and anemia.









